Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
Oncolytics Biotech Inc. announced that it has been granted U.S. Patent 7,264,798 entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus." The claims describe a method of using reovirus to prevent Ras-activated cancers from developing drug resistance to chemotherapeutic agents.
"Recent research conducted by the U.S. National Cancer Institute (NCI) and Cornell University demonstrated that administering reovirus in combination with various chemotherapeutic agents potentiates, or enhances tumour-killing, thus preventing the cancer cells from developing drug resistance," said Dr. Matt Coffey, Chief Scientific Officer. "This patent complements the combination REOLYSIN(R) and chemotherapy clinical program that we are pursuing in the U.K."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Yale Researchers Discover New Potential Asthma Therapeutic Targets Related to Parasites and Insects
Protagen Expands Cooperation with Bayer HealthCare
Emergent BioSolutions Announces Appointment of Ronald Richard to the Board of Directors

Deadly combination: new direct trigger for cell death discovered - Understanding the basic mechanisms that lead to cell death is essential for the development of therapies for cancer and other diseases

Bayer: Supervisory Board extends CEO Werner Baumann’s - Contract until the end of April 2024

Restoring vision by gene therapy - Latest scientific findings give hope for people with incurable retinal degeneration
Pantec Biosolutions receives ISO 13485 certification
Stora Enso awarded as Finland’s most startup-friendly company
Genetic screening before embryo transfer fails to improve the chance of a baby

Hero proteins are here to save other proteins - New group of proteins prevent dangerous clumps associated with neurodegenerative diseases
Applied DNA Sciences collaborates with Advanced Coding Systems to produce DNA-embedded microwires
